AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III …
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III …
Annovis Bio has commenced the treatment of first two subjects in a randomised Phase III clinical trial to assess the …
All nine patients in a Phase I investigator-led trial of a personalised kidney cancer vaccine have successfully generated anti-cancer immune …
Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate vaccine …
Breast cancer is the most common cancer among women in the UK, with one in seven women being diagnosed with …
Qlaris Bio has reported positive topline outcomes from two randomised Phase II US trials, Osprey and Apteryx, of QLS 111 …
The use of a spinal cord stimulation (SCS) device has the potential to gradually reawaken functionally silent motor neurons and …
As global supply chains come under increasing strain and AI disrupts how clinical trials are conducted, experts will congregate to …
US-based immuno-dermatology company Alys Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) and Health Canada for …
A US university has launched a prevention trial examining the use of Eli Lilly’s investigational remternetug in young adults to …
Israeli pharmaceutical company RedHill Biopharma has initiated a placebo-controlled Phase II trial to assess the combination of opaganib and darolutamide …
US-based pharmaceutical company Cumberland Pharmaceuticals has reported positive top-line outcomes from a Phase II trial of ifetroban as a potential …
Italian research charity Telethon Foundation is one step closer to getting a gene therapy to treat rare disease Wiskott-Aldrich syndrome …
Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures glucose levels from a …
A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options …